Old Web
English
Sign In
Acemap
>
Paper
>
15966 Rates of malignancies through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials
15966 Rates of malignancies through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials
2020
Jennifer Clay Cather
Beatrice Nardone
Jeff Parno
Alan M. Mendelsohn
Stephen J. Rozzo
Elizabeth N. Ergen
Keywords:
Medicine
Tildrakizumab
Internal medicine
Clinical trial
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]